WO2012153729A1 - ヘテロ芳香環誘導体 - Google Patents
ヘテロ芳香環誘導体 Download PDFInfo
- Publication number
- WO2012153729A1 WO2012153729A1 PCT/JP2012/061745 JP2012061745W WO2012153729A1 WO 2012153729 A1 WO2012153729 A1 WO 2012153729A1 JP 2012061745 W JP2012061745 W JP 2012061745W WO 2012153729 A1 WO2012153729 A1 WO 2012153729A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- mmol
- ethyl
- reaction
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 5
- 208000030814 Eating disease Diseases 0.000 claims abstract description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 5
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 5
- 206010020772 Hypertension Diseases 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 208000002193 Pain Diseases 0.000 claims abstract description 5
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 5
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 5
- 230000002124 endocrine Effects 0.000 claims abstract description 5
- 206010015037 epilepsy Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 208000019906 panic disease Diseases 0.000 claims abstract description 5
- 208000019116 sleep disease Diseases 0.000 claims abstract description 5
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 4
- 208000020685 sleep-wake disease Diseases 0.000 claims abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 55
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- 125000001425 triazolyl group Chemical group 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 150000004292 cyclic ethers Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 230000001079 digestive effect Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 255
- 102000002512 Orexin Human genes 0.000 abstract description 16
- 108060005714 orexin Proteins 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 3
- 239000002464 receptor antagonist Substances 0.000 abstract description 2
- 229940044551 receptor antagonist Drugs 0.000 abstract description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 149
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 88
- 239000000243 solution Substances 0.000 description 84
- 239000002904 solvent Substances 0.000 description 82
- 238000001819 mass spectrum Methods 0.000 description 77
- -1 for example Chemical class 0.000 description 70
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 65
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 60
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 239000000203 mixture Substances 0.000 description 46
- 239000007787 solid Substances 0.000 description 45
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 40
- 230000002829 reductive effect Effects 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 239000007858 starting material Substances 0.000 description 27
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- 239000012044 organic layer Substances 0.000 description 22
- 238000004440 column chromatography Methods 0.000 description 20
- 230000014759 maintenance of location Effects 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 19
- 239000010410 layer Substances 0.000 description 19
- 239000011734 sodium Substances 0.000 description 19
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 239000012046 mixed solvent Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 238000006482 condensation reaction Methods 0.000 description 14
- 239000002274 desiccant Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 108050000742 Orexin Receptor Proteins 0.000 description 13
- 102000008834 Orexin receptor Human genes 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 12
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 11
- 238000005804 alkylation reaction Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 10
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 235000011121 sodium hydroxide Nutrition 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000003042 antagnostic effect Effects 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000010511 deprotection reaction Methods 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- UTENUPFWBIFKPW-UHFFFAOYSA-N 2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1N=CC=N1 UTENUPFWBIFKPW-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000004210 ether based solvent Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 150000003008 phosphonic acid esters Chemical class 0.000 description 5
- 239000002798 polar solvent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QJVHGXRDNSNZLI-UHFFFAOYSA-N 2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]-n-methylethanamine;hydrochloride Chemical compound Cl.N1=C(CCNC)C=CN1C1=CC=C(F)C=N1 QJVHGXRDNSNZLI-UHFFFAOYSA-N 0.000 description 4
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- SRBAGFIYKNQXDV-UHFFFAOYSA-N 5-methyl-2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=CC(C)=CC=C1N1N=CC=N1 SRBAGFIYKNQXDV-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- BZXPFBYXSVHIHK-UHFFFAOYSA-N N-(triazol-2-yl)benzamide Chemical compound C(C1=CC=CC=C1)(=O)NN1N=CC=N1 BZXPFBYXSVHIHK-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000005456 alcohol based solvent Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 238000006146 oximation reaction Methods 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- IVEBVDPQAWDNRD-UHFFFAOYSA-N tert-butyl n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]carbamate Chemical compound N1=C(CCNC(=O)OC(C)(C)C)C=CN1C1=CC=C(F)C=N1 IVEBVDPQAWDNRD-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 3
- HXUZXTFWUZBZID-RUDMXATFSA-N (NE)-N-[(5-fluoropyridin-2-yl)methylidene]hydroxylamine Chemical compound O\N=C\C1=CC=C(F)C=N1 HXUZXTFWUZBZID-RUDMXATFSA-N 0.000 description 3
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- ZINFERHOZSULPZ-UHFFFAOYSA-N 2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]acetic acid Chemical compound N1=C(CC(=O)O)C=CN1C1=CC=C(F)C=N1 ZINFERHOZSULPZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- OAYFFUSZSXAYGJ-UHFFFAOYSA-N ethyl 1-(5-fluoropyridin-2-yl)pyrazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)C=CN1C1=CC=C(F)C=N1 OAYFFUSZSXAYGJ-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000000752 ionisation method Methods 0.000 description 3
- QOGDQPHAWXOWFB-UHFFFAOYSA-N n-ethyl-2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethanamine Chemical compound N1=C(CCNCC)C=CN1C1=CC=C(F)C=N1 QOGDQPHAWXOWFB-UHFFFAOYSA-N 0.000 description 3
- OOVYNNAVASMQLW-UHFFFAOYSA-N n-ethyl-2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethanamine;hydrochloride Chemical compound Cl.N1=C(CCNCC)C=CN1C1=CC=C(F)C=N1 OOVYNNAVASMQLW-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 3
- YWNRNHKXZGHYNO-UHFFFAOYSA-N tert-butyl n-(3-amino-3-hydroxyiminopropyl)-n-ethylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC)CCC(N)=NO YWNRNHKXZGHYNO-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- KQFKPRKCARUNAF-UHFFFAOYSA-N 1-(5-fluoropyridin-2-yl)pyrazole-3-carbaldehyde Chemical compound N1=CC(F)=CC=C1N1N=C(C=O)C=C1 KQFKPRKCARUNAF-UHFFFAOYSA-N 0.000 description 2
- MUUDQJPFYGEHFO-UHFFFAOYSA-N 1-(5-fluoropyridin-2-yl)pyrazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)C=CN1C1=CC=C(F)C=N1 MUUDQJPFYGEHFO-UHFFFAOYSA-N 0.000 description 2
- AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- QRNKXBTUKXAGHN-UHFFFAOYSA-N 2-(1h-pyrazol-4-yl)ethanamine;dihydrochloride Chemical compound Cl.Cl.NCCC=1C=NNC=1 QRNKXBTUKXAGHN-UHFFFAOYSA-N 0.000 description 2
- DFAKAPWWCZDGBK-UHFFFAOYSA-N 2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]-n-methylacetamide Chemical compound N1=C(CC(=O)NC)C=CN1C1=CC=C(F)C=N1 DFAKAPWWCZDGBK-UHFFFAOYSA-N 0.000 description 2
- IRWYKNBBBIXALU-UHFFFAOYSA-N 2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]-n-methylethanamine Chemical compound N1=C(CCNC)C=CN1C1=CC=C(F)C=N1 IRWYKNBBBIXALU-UHFFFAOYSA-N 0.000 description 2
- YPBIBFXEJIYVQY-UHFFFAOYSA-N 2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethanamine;dihydrochloride Chemical compound Cl.Cl.N1=C(CCN)C=CN1C1=CC=C(F)C=N1 YPBIBFXEJIYVQY-UHFFFAOYSA-N 0.000 description 2
- GLOUPBZVFSPASA-UHFFFAOYSA-N 2-[1-(oxan-2-yl)pyrazol-3-yl]ethanamine Chemical compound N1=C(CCN)C=CN1C1OCCCC1 GLOUPBZVFSPASA-UHFFFAOYSA-N 0.000 description 2
- NNHZOUZQHWXVMS-UHFFFAOYSA-N 2-[3-(5-fluoropyridin-2-yl)-1,2-oxazol-5-yl]ethanamine Chemical compound O1C(CCN)=CC(C=2N=CC(F)=CC=2)=N1 NNHZOUZQHWXVMS-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- PDFUQMWDCHZFTG-UHFFFAOYSA-N 3-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]propanoic acid Chemical compound N1=C(CCC(=O)O)C=CN1C1=CC=C(F)C=N1 PDFUQMWDCHZFTG-UHFFFAOYSA-N 0.000 description 2
- RZVYWCCWSASURQ-UHFFFAOYSA-N 3-[1-(oxan-2-yl)pyrazol-3-yl]propanoic acid Chemical compound N1=C(CCC(=O)O)C=CN1C1OCCCC1 RZVYWCCWSASURQ-UHFFFAOYSA-N 0.000 description 2
- HCYLTPJADJTYPX-UHFFFAOYSA-N 5-fluoro-2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1N1N=CC=N1 HCYLTPJADJTYPX-UHFFFAOYSA-N 0.000 description 2
- MQZMZXRPIQNSDV-UHFFFAOYSA-N 5-methyl-n-[2-(1h-pyrazol-4-yl)ethyl]-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)NCCC=1C=NNC=1 MQZMZXRPIQNSDV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 2
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- CTACXYVHMSKGBN-UHFFFAOYSA-N [1-(5-fluoropyridin-2-yl)pyrazol-3-yl]methanol Chemical compound N1=C(CO)C=CN1C1=CC=C(F)C=N1 CTACXYVHMSKGBN-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- BSFFSGJZEMTCRI-UHFFFAOYSA-N benzyl N-[2-[1-(oxan-2-yl)pyrazol-3-yl]ethyl]carbamate Chemical compound C(C1=CC=CC=C1)OC(NCCC1=NN(C=C1)C1OCCCC1)=O BSFFSGJZEMTCRI-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- MZFIPUGCDMVMCU-GQCTYLIASA-N ethyl (e)-3-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]prop-2-enoate Chemical compound N1=C(/C=C/C(=O)OCC)C=CN1C1=CC=C(F)C=N1 MZFIPUGCDMVMCU-GQCTYLIASA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LGUPCYLHFSEKHI-UHFFFAOYSA-N n-(2-cyanoethyl)-2-(triazol-2-yl)benzamide Chemical compound N#CCCNC(=O)C1=CC=CC=C1N1N=CC=N1 LGUPCYLHFSEKHI-UHFFFAOYSA-N 0.000 description 2
- KYBBCCMFMZLPOJ-UHFFFAOYSA-N n-(2-cyanoethyl)-5-methyl-2-(triazol-2-yl)benzamide Chemical compound N#CCCNC(=O)C1=CC(C)=CC=C1N1N=CC=N1 KYBBCCMFMZLPOJ-UHFFFAOYSA-N 0.000 description 2
- LEMOPBSXHGCVNI-UHFFFAOYSA-N n-(3,3-diethoxypropyl)-5-methyl-2-(triazol-2-yl)benzamide Chemical compound CCOC(OCC)CCNC(=O)C1=CC(C)=CC=C1N1N=CC=N1 LEMOPBSXHGCVNI-UHFFFAOYSA-N 0.000 description 2
- XXHORTORBVBKHY-UHFFFAOYSA-N n-[2-(1h-imidazol-5-yl)ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)NCCC1=CNC=N1 XXHORTORBVBKHY-UHFFFAOYSA-N 0.000 description 2
- SYEUBZSSZORXBR-UHFFFAOYSA-N n-[2-(1h-pyrazol-4-yl)ethyl]-2-(triazol-2-yl)benzamide Chemical compound C=1C=CC=C(N2N=CC=N2)C=1C(=O)NCCC=1C=NNC=1 SYEUBZSSZORXBR-UHFFFAOYSA-N 0.000 description 2
- RDEVRWZERYVLJH-UHFFFAOYSA-N n-ethyl-2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]acetamide Chemical compound N1=C(CC(=O)NCC)C=CN1C1=CC=C(F)C=N1 RDEVRWZERYVLJH-UHFFFAOYSA-N 0.000 description 2
- PGAKSFSUBUWIBG-UHFFFAOYSA-N n-ethyl-n-[2-(1h-pyrazol-5-yl)ethyl]-2-(triazol-2-yl)benzamide Chemical compound C=1C=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC=1C=CNN=1 PGAKSFSUBUWIBG-UHFFFAOYSA-N 0.000 description 2
- DTGMUXBSVJRZKL-UHFFFAOYSA-N n-ethyl-n-[2-[1-(4-fluorophenyl)pyrazol-3-yl]ethyl]-2-(triazol-2-yl)benzamide Chemical compound C=1C=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(=N1)C=CN1C1=CC=C(F)C=C1 DTGMUXBSVJRZKL-UHFFFAOYSA-N 0.000 description 2
- RHXGFAJHZUVODK-UHFFFAOYSA-N n-ethyl-n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]-5-methyl-2-pyrimidin-2-ylbenzamide Chemical compound C=1C(C)=CC=C(C=2N=CC=CN=2)C=1C(=O)N(CC)CCC(=N1)C=CN1C1=CC=C(F)C=N1 RHXGFAJHZUVODK-UHFFFAOYSA-N 0.000 description 2
- PJNZEGFQYQCTKE-UHFFFAOYSA-N n-ethyl-n-[2-[3-(5-fluoropyridin-2-yl)-1,2-oxazol-5-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(ON=1)=CC=1C1=CC=C(F)C=N1 PJNZEGFQYQCTKE-UHFFFAOYSA-N 0.000 description 2
- ZGYSLWFZMKJTEP-UHFFFAOYSA-N n-ethyl-n-[2-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(N=1)=NOC=1C1=CC=C(F)C=C1 ZGYSLWFZMKJTEP-UHFFFAOYSA-N 0.000 description 2
- LQZYBZGINWSWAN-UHFFFAOYSA-N n-ethyl-n-[2-[5-(5-fluoropyridin-2-yl)-1,2-oxazol-3-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(=NO1)C=C1C1=CC=C(F)C=N1 LQZYBZGINWSWAN-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 2
- 229940071536 silver acetate Drugs 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XRDFAXVFALILIJ-UHFFFAOYSA-N tert-butyl n-(2-cyanoethyl)-n-ethylcarbamate Chemical compound N#CCCN(CC)C(=O)OC(C)(C)C XRDFAXVFALILIJ-UHFFFAOYSA-N 0.000 description 2
- HVCMKAXDTUHGFL-UHFFFAOYSA-N tert-butyl n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]-n-methylcarbamate Chemical compound N1=C(CCN(C)C(=O)OC(C)(C)C)C=CN1C1=CC=C(F)C=N1 HVCMKAXDTUHGFL-UHFFFAOYSA-N 0.000 description 2
- YEGFJURLXPOOSA-UHFFFAOYSA-N tert-butyl n-[2-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-n-ethylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC)CCC1=NOC(C=2C=C(F)C(F)=CC=2)=N1 YEGFJURLXPOOSA-UHFFFAOYSA-N 0.000 description 2
- LBODZJRDXWRNAU-UHFFFAOYSA-N tert-butyl n-ethyl-n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]carbamate Chemical compound N1=C(CCN(CC)C(=O)OC(C)(C)C)C=CN1C1=CC=C(F)C=N1 LBODZJRDXWRNAU-UHFFFAOYSA-N 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- JRHPOFJADXHYBR-UHFFFAOYSA-N 1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CNC1CCCCC1NC JRHPOFJADXHYBR-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- LJKATJHBJPFKBQ-UHFFFAOYSA-N 2-(oxan-2-yl)pyrazole-3-carbaldehyde Chemical compound O=CC1=CC=NN1C1OCCCC1 LJKATJHBJPFKBQ-UHFFFAOYSA-N 0.000 description 1
- RQQJUDHYJQURRJ-UHFFFAOYSA-N 2-[2-[3-(5-fluoropyridin-2-yl)-1,2-oxazol-5-yl]ethyl]isoindole-1,3-dione Chemical compound N1=CC(F)=CC=C1C1=NOC(CCN2C(C3=CC=CC=C3C2=O)=O)=C1 RQQJUDHYJQURRJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ADHFFWPXLYKYOP-UHFFFAOYSA-N 2-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]-n-ethylethanamine Chemical compound CCNCCC1=NOC(C=2C=C(F)C(F)=CC=2)=N1 ADHFFWPXLYKYOP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- KHCIVRLMGQEZPB-UHFFFAOYSA-N 2-ethynyl-5-fluoropyridine Chemical compound FC1=CC=C(C#C)N=C1 KHCIVRLMGQEZPB-UHFFFAOYSA-N 0.000 description 1
- BCLGTIBYZQQFJW-UHFFFAOYSA-N 2-pyrimidin-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=NC=CC=N1 BCLGTIBYZQQFJW-UHFFFAOYSA-N 0.000 description 1
- PXXMSHBZYAOHBD-UHFFFAOYSA-N 3,3-diethoxypropan-1-amine Chemical compound CCOC(CCN)OCC PXXMSHBZYAOHBD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FHSIWYUEJOTTGV-UHFFFAOYSA-N 3-chloro-2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)c1cccc(Cl)c1-n1nccn1 FHSIWYUEJOTTGV-UHFFFAOYSA-N 0.000 description 1
- IBQJAAIBLGSGSO-UHFFFAOYSA-N 3-methyl-2-(triazol-2-yl)benzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1N1N=CC=N1 IBQJAAIBLGSGSO-UHFFFAOYSA-N 0.000 description 1
- DQCFZKMYQFHPPZ-UHFFFAOYSA-N 5-chloro-n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]-n-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(Cl)=CC=C(N2N=CC=N2)C=1C(=O)N(C)CCC(=N1)C=CN1C1=CC=C(F)C=N1 DQCFZKMYQFHPPZ-UHFFFAOYSA-N 0.000 description 1
- SOPVTFMDLFUAJE-UHFFFAOYSA-N 5-fluoro-n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]-n-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(F)=CC=C(N2N=CC=N2)C=1C(=O)N(C)CCC(=N1)C=CN1C1=CC=C(F)C=N1 SOPVTFMDLFUAJE-UHFFFAOYSA-N 0.000 description 1
- IACCXWQKIQUVFQ-UHFFFAOYSA-N 5-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC=C(C=O)N=C1 IACCXWQKIQUVFQ-UHFFFAOYSA-N 0.000 description 1
- JTKFIIQGMVKDNZ-UHFFFAOYSA-N 5-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(F)C=N1 JTKFIIQGMVKDNZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 0 C*(*)(CC=*1)CC=C1NC=CC(CCN)=N Chemical compound C*(*)(CC=*1)CC=C1NC=CC(CCN)=N 0.000 description 1
- ZVBVEZYQDHWUOE-NOYHPSALSA-N CNCCC(/C=C\Nc(nc1)ccc1F)=N Chemical compound CNCCC(/C=C\Nc(nc1)ccc1F)=N ZVBVEZYQDHWUOE-NOYHPSALSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101500025902 Homo sapiens Orexin-A Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100037757 Orexin Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000004517 catalytic hydrocracking Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006705 deacetalization reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MSPOSRHJXMILNK-UHFFFAOYSA-N ethyl 1h-pyrazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=NN1 MSPOSRHJXMILNK-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003796 lateral hypothalamic area Anatomy 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- XFLYIACWMFBDKP-UHFFFAOYSA-N n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]-n,5-dimethyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(C)CCC(=N1)C=CN1C1=CC=C(F)C=N1 XFLYIACWMFBDKP-UHFFFAOYSA-N 0.000 description 1
- PPTVPLCBMLMYSE-UHFFFAOYSA-N n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-4-yl]ethyl]-2-(triazol-2-yl)benzamide Chemical compound N1=CC(F)=CC=C1N1N=CC(CCNC(=O)C=2C(=CC=CC=2)N2N=CC=N2)=C1 PPTVPLCBMLMYSE-UHFFFAOYSA-N 0.000 description 1
- MQJBKNBUPJOMHB-UHFFFAOYSA-N n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-4-yl]ethyl]-n,5-dimethyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(C)CCC(=C1)C=NN1C1=CC=C(F)C=N1 MQJBKNBUPJOMHB-UHFFFAOYSA-N 0.000 description 1
- LEAAEADQCNYIDS-UHFFFAOYSA-N n-[2-[3-(5-fluoropyridin-2-yl)-1,2-oxazol-5-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)NCCC(ON=1)=CC=1C1=CC=C(F)C=N1 LEAAEADQCNYIDS-UHFFFAOYSA-N 0.000 description 1
- MROOIZDNEIQZLU-UHFFFAOYSA-N n-[2-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)NCCC(N=1)=NOC=1C1=CC=C(F)C=N1 MROOIZDNEIQZLU-UHFFFAOYSA-N 0.000 description 1
- SDECPLOYPMATMA-UHFFFAOYSA-N n-[2-[5-(5-fluoropyridin-2-yl)-1,2-oxazol-3-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)NCCC(=NO1)C=C1C1=CC=C(F)C=N1 SDECPLOYPMATMA-UHFFFAOYSA-N 0.000 description 1
- JYKNTUQCUZUJPP-UHFFFAOYSA-N n-[2-[5-(5-fluoropyridin-2-yl)-1,2-oxazol-3-yl]ethyl]-n,5-dimethyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(C)CCC(=NO1)C=C1C1=CC=C(F)C=N1 JYKNTUQCUZUJPP-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IBDUCXXUSPIFNT-UHFFFAOYSA-N n-ethyl-2-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]ethanamine Chemical compound CCNCCC1=NOC(C=2C=CC(F)=CC=2)=N1 IBDUCXXUSPIFNT-UHFFFAOYSA-N 0.000 description 1
- PPMZWRYFCOJTRU-UHFFFAOYSA-N n-ethyl-4-fluoro-n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]-2-(triazol-2-yl)benzamide Chemical compound C=1C=C(F)C=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(=N1)C=CN1C1=CC=C(F)C=N1 PPMZWRYFCOJTRU-UHFFFAOYSA-N 0.000 description 1
- PGGDWSQZTGWCEA-UHFFFAOYSA-N n-ethyl-5-fluoro-n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]-2-(triazol-2-yl)benzamide Chemical compound C=1C(F)=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(=N1)C=CN1C1=CC=C(F)C=N1 PGGDWSQZTGWCEA-UHFFFAOYSA-N 0.000 description 1
- HRCOZYYILAJZGL-UHFFFAOYSA-N n-ethyl-n-[2-[1-(5-fluoropyridin-2-yl)imidazol-4-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(N=C1)=CN1C1=CC=C(F)C=N1 HRCOZYYILAJZGL-UHFFFAOYSA-N 0.000 description 1
- XHZDJNLMAQYXQU-UHFFFAOYSA-N n-ethyl-n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-3-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(=N1)C=CN1C1=CC=C(F)C=N1 XHZDJNLMAQYXQU-UHFFFAOYSA-N 0.000 description 1
- ZQWTYERKLJPPPN-UHFFFAOYSA-N n-ethyl-n-[2-[1-(5-fluoropyridin-2-yl)pyrazol-4-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(=C1)C=NN1C1=CC=C(F)C=N1 ZQWTYERKLJPPPN-UHFFFAOYSA-N 0.000 description 1
- AJUIDXGPKBVVMP-UHFFFAOYSA-N n-ethyl-n-[2-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]ethyl]-5-methyl-2-(triazol-2-yl)benzamide Chemical compound C=1C(C)=CC=C(N2N=CC=N2)C=1C(=O)N(CC)CCC(N=1)=NOC=1C1=CC=C(F)C=N1 AJUIDXGPKBVVMP-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000008452 non REM sleep Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- ORIHZIZPTZTNCU-YVMONPNESA-N salicylaldoxime Chemical compound O\N=C/C1=CC=CC=C1O ORIHZIZPTZTNCU-YVMONPNESA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NORLFIHQJFOIGS-UHFFFAOYSA-N tert-butyl n-(2-cyanoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCC#N NORLFIHQJFOIGS-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 210000004515 ventral tegmental area Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a compound having an orexin (OX) receptor antagonistic action and a pharmaceutically acceptable salt thereof, and sleep disorders, depressions, anxiety disorders, panic disorders, schizophrenia, drug dependence containing them as active ingredients
- OX orexin
- the present invention relates to a therapeutic or prophylactic agent for diseases such as infectious diseases, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, pain, digestive disorders, epilepsy, inflammation, immune related diseases, endocrine related diseases, and hypertension.
- Orexin is a neuropeptide spliced from preproorexin that is specifically expressed in the lateral hypothalamic area. So far, OX-A consisting of 33 amino acids and OX-B consisting of 28 amino acids have been identified, both of which are deeply involved in the regulation of sleep / wake patterns and the regulation of food intake. .
- OX-A and OX-B act on the OX receptor.
- the OX receptor has been previously cloned into two subtypes of OX1 and OX2 receptors, both of which are known to be 7-transmembrane G protein-coupled receptors that are mainly expressed in the brain. .
- the OX1 receptor is specifically conjugated to Gq in the G protein subclass, while the OX2 receptor is conjugated to Gq and Gi / o (see Non-Patent Document 1 and Non-Patent Document 2).
- the tissue distribution varies depending on the subtype of the OX receptor.
- the OX1 receptor has a high density in the locus coeruleus, the origin of noradrenergic nerves, and the OX2 receptor in the nodule papillary nucleus, the origin of histamine neurons. (See Non-Patent Document 3, Non-Patent Document 4 and Non-Patent Document 5). Expression of both the OX1 receptor and the OX2 receptor is observed in the raphe nucleus which is the origin nucleus of the serotonin nerve and the ventral tegmental area which is the origin nucleus of the dopamine nerve (see Non-Patent Document 3). Orexin neurons project to the brain stem and the monoamine nervous system in the hypothalamus and have an excitatory effect on those nerves.
- OX2 receptors are also seen in the acetylcholine neurons of the brain stem involved in REM sleep control. It also affects the activity of these nerve nuclei (see Non-Patent Document 3 and Non-Patent Document 4).
- Non-Patent Document 10 As OX receptor antagonistic compounds, for example, compounds having various structures described in Non-Patent Document 11 as a review are known.
- the object of the present invention is to find a novel compound having an OX receptor antagonistic action, sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's chorea, feeding
- the object is to provide a therapeutic or prophylactic agent for diseases such as disorders, pain, gastrointestinal diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases, or hypertension. More specifically, it is to provide a novel compound exhibiting excellent pharmacokinetics and safety as well as excellent OX receptor antagonism.
- R 1 represents a hydrogen atom, a halogen atom, or a C 1-6 alkyl group
- R 2 represents a hydrogen atom, a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 substituents selected from substituent group 1), C 3 -6 cycloalkyl group or a 4-6 membered cyclic ether group
- Substituent group 1 is a group consisting of a halogen atom, a C 3-6 cycloalkyl group, and a C 1-6 alkoxy group
- R 3 represents a triazolyl group, a pyridyl group, or a pyrimidinyl group; The triazolyl group, pyridyl group and pyrimidinyl group may be substituted with 1 to 3 halogen atoms
- R 4 and R 5 are the same or different and each represents a hydrogen atom, a halogen atom, or a C 1-6 al
- R 4 is a halogen atom
- R 5 is a hydrogen atom or a halogen atom, or a pharmaceutically acceptable salt thereof
- R 1 represents a hydrogen atom, a halogen atom, or a C 1-6 alkyl group
- R 2 represents a hydrogen atom, a C 1-6 alkyl group (the C 1-6 alkyl group may be substituted with 1 to 3 substituents selected from Substituent Group 1)
- Substituent group 1 is a group consisting of a halogen atom, a C 3-6 cycloalkyl group, and a C 1-6 alkoxy group
- R 3 represents a triazolyl group, a pyridyl group, or a pyrimidinyl group; The triazolyl group, pyridyl group and pyrimidinyl group may be substituted with 1 to 3 halogen atoms
- R 4 represents a hydrogen atom, a halogen atom, or a C 1-6 alkyl group
- X is a nitrogen atom
- R 2 is a C 1-6 alkyl group
- R 3 is a triazolyl group or a pyrimidinyl group
- a pharmaceutical composition comprising the heteroaromatic ring derivative according to any one of (1) to (5) above or a pharmaceutically acceptable salt thereof as an active ingredient, and (7) the above (1) Sleep disorder, depression, anxiety disorder, panic disorder, integration characterized by containing the heteroaromatic ring derivative according to any one of (5) or a pharmaceutically acceptable salt thereof as an active ingredient
- diseases such as ataxia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorders,
- heteroaromatic ring derivative of the present invention exhibits affinity for the OX receptor and antagonizes the stimulation of the receptor by a physiological ligand.
- halogen atom is a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
- C 1-6 alkyl group means a linear or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec -Butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethylpropyl, n-hexyl, isohexyl, neohexyl group and the like can be mentioned.
- the “C 3-6 cycloalkyl group” is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl group.
- the “4-6 membered cyclic ether group” is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl group.
- C 1-6 alkoxy group means a linear or branched alkoxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec -Butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, 1-ethylpropoxy, n-hexyloxy group and the like can be mentioned.
- “pharmaceutically acceptable salt” means a pharmaceutically acceptable acid addition salt, and the acid used includes sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, or Salt with inorganic acid such as nitric acid, or acetic acid, benzoic acid, oxalic acid, lactic acid, malic acid, tartaric acid, fumaric acid, maleic acid, citric acid, malonic acid, mandelic acid, gluconic acid, galactaric acid, glucoheptonic acid, Examples include salts with organic acids such as glycolic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, or naphthalene-2-sulfonic acid. Conversion from the educt to the salt can be performed by conventional methods.
- a compound in which X is a nitrogen atom is preferable.
- Y is preferably a compound of any one of the following formula group (IIa).
- R 1 is preferably a hydrogen atom, a halogen atom other than iodine, or a C 1-6 alkyl group, and more preferably a hydrogen atom, a fluorine atom, a chlorine atom, or a methyl group.
- R 2 is preferably a compound having a C 1-6 alkyl group, more preferably a compound having a methyl group or an ethyl group.
- R 3 is preferably a compound which is a triazolyl group or a pyrimidinyl group, more preferably a 1,2,3-triazol-2-yl group or a pyrimidin-2-yl group.
- R 4 is preferably a halogen atom compound, more preferably a compound other than iodine, more preferably a fluorine atom or a chlorine atom, and most preferably a fluorine atom.
- R 5 is preferably a hydrogen atom or a halogen atom, and more preferably a hydrogen atom or a fluorine atom.
- Examples of preferred compounds in the compounds of the present invention include N-ethyl-N- ⁇ 2- [1- (5-fluoropyridin-2-yl) -1H-pyrazol-4-yl] ethyl ⁇ -5-methyl-2- (2H-1,2,3-triazole -2-yl) benzamide, N- ⁇ 2- [1- (5-fluoropyridin-2-yl) -1H-pyrazol-4-yl] ethyl ⁇ -N, 5-dimethyl-2- (2H-1,2,3-triazole-2 -Yl) benzamide, N-ethyl-N- ⁇ 2- [1- (5-fluoropyridin-2-yl) -1H-pyrazol-4-yl] ethyl ⁇ -2- (2H-1,2,3-triazol-2-yl Benzamide, N-ethyl-N- ⁇ 2- [1- (5-fluoropyridin-2-yl) -1H-pyra
- the compounds of the present invention include all enantiomers, diastereomers, equilibrium compounds, mixtures of these in any proportion, racemates and the like.
- the compounds according to the present invention also include compounds in which one or more hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms and fluorine atoms are substituted with radioactive isotopes or stable isotopes. These labeled compounds are useful for metabolic and pharmacokinetic studies, biological ligands, etc. as receptor ligands.
- the compound according to the present invention can be administered orally or parenterally.
- the dosage forms are tablets, capsules, granules, powders, powders, troches, ointments, creams, skin patches, emulsions, suspensions, suppositories, injections, etc., all of which are conventional formulations It can be manufactured by technology (for example, the method prescribed in the 15th revision Japanese Pharmacopoeia). These dosage forms can be appropriately selected according to the patient's symptoms, age, weight, and purpose of treatment.
- These formulations are pharmaceutically acceptable carriers for the compositions containing the compounds of the invention, ie excipients (eg crystalline cellulose, starch, lactose, mannitol), binders (eg hydroxypropylcellulose).
- the compound of the present invention can be orally or parenterally administered to an adult patient at a dosage of 0.001 to 500 mg once or several times a day.
- the dose can be appropriately increased or decreased depending on the type of disease to be treated, the age, weight, symptoms, etc. of the patient.
- a 1 and A 2 represent a halogen atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group or a trifluoromethanesulfonyloxy group, and other symbols are as defined above.
- Step A-1 The compound (3) can be obtained by a condensation reaction of the compound (1) and the compound (2).
- the reaction in Step A-1 can be carried out by a general method for amidation of carboxylic acid. Examples thereof include a method of reacting a carboxylic acid with an amine after introducing the carboxylic acid to a carboxylic acid halide such as carboxylic acid chloride or carboxylic acid bromide, and a method of reacting the carboxylic acid with an amine in the presence of a dehydrating condensing agent. All of these reactions can be carried out in a solvent in the presence or absence of a base.
- Examples of the halogenating agent used in this reaction include thionyl chloride, oxalyl chloride, phosphorus oxychloride and phosphorus oxybromide.
- Examples of the dehydrating condensing agent used in this reaction include 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide / hydrochloride, propanephosphonic acid anhydride, dicyclohexylcarbodiimide, diphenylphosphonyl azide, carbonyldiimidazole and the like.
- Activating agents such as 1-hydroxybenzotriazole and hydroxysuccinimide can be used as necessary.
- Solvents used in this reaction include ether solvents such as tetrahydrofuran and 1,4-dioxane, aprotic polar solvents such as N, N-dimethylformamide and acetonitrile, halogen solvents such as dichloromethane and chloroform, and toluene.
- An aromatic hydrocarbon solvent, ethyl acetate, or a mixed solvent thereof can be used.
- Examples of the base used in this reaction include organic amines such as pyridine, triethylamine and diisopropylethylamine, and inorganic bases such as potassium carbonate, sodium carbonate and sodium bicarbonate. This reaction can be carried out usually at 0 ° C. to 150 ° C., preferably 25 ° C. to 80 ° C.
- Step A-2 Compound (5) can be obtained by a coupling reaction of compound (3) and compound (4).
- the reaction in Step A-2 can be performed by a general method in which an aromatic ring is substituted with a nitrogen atom of an azole compound using a catalyst and a ligand in the presence of a base.
- the catalyst used in this reaction include copper catalysts such as copper (0), copper (I) iodide, copper (I) chloride, and copper (I) oxide.
- Examples of the ligand used in this reaction include N, N′-dimethylethylenediamine, N, N′-dimethylcyclohexane-1,2-diamine, 2-aminopyridine, 1,10-phenanthroline, 2-hydroxybenzaldehyde oxime, and the like. Is mentioned.
- Examples of the base used in this reaction include potassium carbonate, potassium phosphate, potassium hydroxide, tert-butoxypotassium, cesium carbonate, sodium carbonate, sodium bicarbonate, sodium acetate, sodium methoxide, tetrabutylammonium hydroxide and the like.
- Solvents used in this reaction include alcohol solvents such as methanol and ethanol, ether solvents such as tetrahydrofuran and 1,4-dioxane, aprotic polar solvents such as N, N-dimethylformamide, dimethyl sulfoxide and acetonitrile, dichloromethane , Halogen solvents such as chloroform, aromatic hydrocarbon solvents such as toluene, water, or a mixed solvent thereof.
- This reaction can be carried out usually at 0 ° C. to 150 ° C., preferably 25 ° C. to 100 ° C.
- Step A-3 The compound (Ia) of the present invention can be obtained by an alkylation reaction of the compound (5).
- the reaction in Step A-3 can be carried out by a general amide alkylation method.
- Bases used in this reaction include inorganic bases such as sodium hydride, sodium hydroxide, sodium carbonate, potassium carbonate and cesium carbonate, metal lower alkoxides such as sodium ethoxide and tert-butoxypotassium, and organic such as triethylamine and diisopropylethylamine.
- a base is a general amide alkylation method.
- Bases used in this reaction include inorganic bases such as sodium hydride, sodium hydroxide, sodium carbonate, potassium carbonate and cesium carbonate, metal lower alkoxides such as sodium ethoxide and tert-butoxypotassium, and organic such as triethylamine and diisopropylethylamine.
- Solvents used in this reaction include alcohol solvents such as methanol and ethanol, ether solvents such as tetrahydrofuran and 1,4-dioxane, aprotic polar solvents such as N, N-dimethylformamide, dimethyl sulfoxide and acetonitrile, dichloromethane , Halogen solvents such as chloroform, aromatic hydrocarbon solvents such as toluene, water, or a mixed solvent thereof.
- This reaction can be carried out usually at 0 ° C. to 150 ° C., preferably 20 ° C. to 100 ° C.
- R 5 is a common protecting group for carboxylic acids, such as J.F.W.McOmie, Protective Groups in Organic Chemistry., And T.W.Greene and P.G.M.Wuts, Protective. (Indicates a group described in Groups in Organic Synthesis. Etc., for example, a C 1-6 alkyl group, a benzyl group, etc. Other symbols are as defined above.)
- the compound (Ib) of the present invention can be produced by the method shown in Scheme B.
- Step B-1 The compound (8) can be obtained by a coupling reaction of the compound (7) and the compound (4).
- the reaction in step B-1 can be carried out according to the same reaction conditions as in step A-2.
- Step B-2 Compound (9) can be obtained by hydrolysis reaction or hydrogenolysis reaction of compound (8).
- the reaction in step B-2 is described in J. Am. F. W. OMcOmie, Protective Groups Organic Chemistry. W. Greene and P. G. M. It can be carried out under the reaction conditions described in Wuts, Protective Groups In Organic Synthesis.
- hydrolysis using a mineral acid such as hydrochloric acid or sulfuric acid, or an inorganic base such as sodium hydroxide or potassium hydroxide
- hydrocracking in the presence of a hydrogen source using a metal catalyst such as palladium or platinum Etc.
- Examples of the solvent used in this reaction include alcohol solvents such as methanol and ethanol, ether solvents such as tetrahydrofuran and 1,4-dioxane, water, and mixed solvents thereof. This reaction can be carried out at 0 ° C. to 100 ° C.
- Step B-3 The compound (10) can be obtained by an Arundt-Icetell type carbon increase reaction of the compound (9).
- the carboxylic acid was first converted to a carboxylic acid chloride by treatment with thionyl chloride, oxalyl chloride or the like in a halogen-based solvent such as dichloromethane or chloroform or an aromatic hydrocarbon solvent such as toluene.
- ⁇ -diazomethylketone by treatment with diazomethane or trimethylsilyldiazomethane in an ether solvent such as acetonitrile or tetrahydrofuran or 1,4-dioxane, and finally an ether system such as tetrahydrofuran or 1,4-dioxane.
- ether solvent such as acetonitrile or tetrahydrofuran or 1,4-dioxane
- an ether system such as tetrahydrofuran or 1,4-dioxane.
- the reaction can be carried out under the condition of reacting with silver oxide, silver acetate or the like in a mixed solvent of a solvent and water.
- Step B-4 The compound (12) can be obtained by a condensation reaction of the compound (10) and the compound (11).
- the reaction in Step B-4 can be carried out according to the same reaction conditions as in Step A-1.
- Step B-5 Compound (13) can be obtained by the reduction reaction of the amide of compound (12).
- the reaction in Step B-5 is carried out by using an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, an aromatic hydrocarbon solvent such as toluene, or a mixed solvent thereof, lithium aluminum hydride.
- Step B-6 The compound (Ib) of the present invention can be obtained by a condensation reaction of the compound (13) and the compound (2).
- the reaction in Step B-6 can be carried out according to the same reaction conditions as in Step A-1.
- Step C-1 The compound (8) can be obtained by a coupling reaction of the compound (7) and the compound (4).
- the reaction in step C-1 can be carried out according to the same reaction conditions as in step A-2.
- Step C-2 Compound (14) can be obtained by the reduction reaction of the ester of Compound (8).
- the reaction in Step C-2 is performed in an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, an aromatic hydrocarbon solvent such as toluene, or a mixed solvent thereof, lithium aluminum hydride,
- the reaction can be carried out under conditions for reaction with a reducing agent such as diisobutylaluminum hydride, sodium borohydride, lithium borohydride and the like. This reaction can be carried out at ⁇ 80 ° C. to 150 ° C., preferably 0 ° C. to 25 ° C.
- Step C-3 The compound (15) can be obtained by oxidation reaction of the hydroxyl group of the compound (14).
- the reaction in Step C-3 is carried out in a halogen-based solvent such as dichloromethane or chloroform, dimethyl sulfoxide or acetonitrile, a desvalent reagent, a hypervalent iodine compound such as 2-iodoxybenzoic acid, pyridinium chlorochromate, pyridinium dichromate, etc.
- the reaction can be carried out under the condition of reacting with an oxidizing agent such as chromate, tetrapropylammonium perruthenate, manganese dioxide. This reaction can be carried out at 0 ° C. to 150 ° C., preferably 25 ° C. to 80 ° C.
- Step C-4 Compound (17) can be obtained by Horner-Wadsworth-Emmons reaction of compound (15).
- the phosphonic acid ester (16) is dissolved in an ether solvent such as tetrahydrofuran or 1,4-dioxane, an aromatic hydrocarbon solvent such as toluene or a mixed solvent thereof, sodium hydride, potassium hydride.
- an ether solvent such as tetrahydrofuran or 1,4-dioxane
- an aromatic hydrocarbon solvent such as toluene or a mixed solvent thereof
- sodium hydride potassium hydride.
- Tert-butoxypotassium sodium bis (trimethylsilyl) amide, lithium bis (trimethylsilyl) amide and the like, followed by reaction with an aldehyde. This reaction can be carried out at 0 ° C to 120 ° C.
- Step C-5 Compound (18) can be obtained by reduction reaction of double bond of compound (17).
- the reaction in Step C-5 is hydrogenated in the presence of a metal catalyst such as palladium or platinum in an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, ethyl acetate or a mixed solvent thereof.
- a metal catalyst such as palladium or platinum
- an alcohol solvent such as methanol or ethanol
- an ether solvent such as tetrahydrofuran or 1,4-dioxane, ethyl acetate or a mixed solvent thereof.
- This reaction can be carried out at 25 ° C to 80 ° C.
- Step C-6 Compound (19) can be obtained by hydrolysis of compound (18).
- the reaction in Step C-6 can be performed according to the same reaction conditions as in Step B-2.
- Step C-7 Compound (20) can be obtained from compound (19) by a reaction via Curtius rearrangement.
- carboxylic acid is first treated with diphenylphosphoric acid azide in an aromatic hydrocarbon solvent such as toluene, and further converted to isocyanate by heating, and then methanol, ethanol, tert-butyl alcohol, benzyl It can be carried out under the condition of reacting with alcohol or the like.
- Step C-8 Compound (21) can be obtained by alkylation reaction of compound (20). The reaction in Step C-8 can be carried out according to the same reaction conditions as in Step A-3.
- Step C-9 Compound (13) can be obtained by deprotection of compound (21).
- the reaction in Step C-9 is carried out in an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, a halogen solvent such as dichloromethane or chloroform, water or a mixed solvent thereof, hydrochloric acid, trifluoro
- the treatment can be carried out under conditions of treatment with acetic acid or the like. This reaction can be carried out at 0 ° C to 80 ° C.
- Step C-10 The compound (Ib) of the present invention can be obtained by a condensation reaction of the compound (13) and the compound (2).
- the reaction in Step C-10 can be carried out according to the same reaction conditions as in Step A-1.
- Step D-1 The compound (23) can be obtained by a condensation reaction of the compound (22) and the compound (2).
- the reaction in Step D-1 can be carried out according to the same reaction conditions as in Step A-1.
- Step D-2 The compound (24) can be obtained by deacetalization reaction of the compound (23).
- the reaction in Step D-2 is carried out by using an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, a halogen solvent such as dichloromethane or chloroform, acetone, water or a mixed solvent thereof, hydrochloric acid,
- the reaction can be carried out under the condition of reacting with an acid such as trifluoroacetic acid or p-toluenesulfonic acid. This reaction can be carried out at 0 ° C to 80 ° C.
- Step D-3 Compound (26) can be obtained by the condensation reaction of compound (24) and hydroxylamine (25).
- the reaction in Step D-3 can be carried out under the condition of reacting with hydroxylamine or its hydrochloride in a solvent in the presence or absence of a base.
- the base used in this reaction include organic amines such as pyridine, triethylamine and diisopropylethylamine, inorganic bases such as sodium hydroxide, potassium hydroxide and sodium bicarbonate, and acetates such as sodium acetate and potassium acetate.
- the solvent used in this reaction include alcohol solvents such as methanol and ethanol, water, and mixed solvents thereof. This reaction can be carried out at 0 ° C. to 100 ° C.
- Step D-4 The compound (29) can be obtained by a isoxazole cyclization reaction after the halogenation reaction of the compound (26).
- the oxime form is first converted into an alcoholic solvent such as methanol or ethanol, an etheric solvent such as tetrahydrofuran or 1,4-dioxane, an aprotic polar solvent such as N, N-dimethylformamide, dichloromethane,
- a halogenated imide compound (27) such as N-bromosuccinimide or N-chlorosuccinimide in a halogenated solvent such as chloroform, an aromatic hydrocarbon solvent such as toluene, water or acetonitrile
- the reaction can be carried out in an ether solvent such as tetrahydrofuran or 1,4-dioxane in the presence of a base such as triethylamine or sodium hydroxide under the conditions for reacting with the alky
- Step D-5 The compound (Ic) of the present invention can be obtained by an alkylation reaction of the compound (29).
- the reaction in Step D-5 can be carried out according to the same reaction conditions as in Step A-3.
- Step E-1 Compound (31) can be obtained by the condensation reaction of compound (30) and hydroxylamine (25). The reaction in Step E-1 can be carried out according to the same reaction conditions as in Step D-3.
- Step E-2 The compound (33) can be obtained by a isoxazole cyclization reaction after the halogenation reaction of the compound (31). The reaction in Step E-2 can be carried out according to the same reaction conditions as in Step D-4.
- Step E-3 Compound (34) can be obtained by deprotection of compound (33).
- the reaction in Step E-3 is hydrazine monohydration in an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, a halogen solvent such as dichloromethane or chloroform, water or a mixed solvent thereof. It can carry out on the conditions made to react with a thing. This reaction can be carried out at 25 ° C to 100 ° C.
- Step E-4 The compound (35) can be obtained by a condensation reaction of the compound (34) and the compound (2).
- the reaction in Step E-4 can be carried out according to the same reaction conditions as in Step A-1.
- Step E-5 The compound (Id) of the present invention can be obtained by an alkylation reaction of the compound (35).
- the reaction in Step E-5 can be carried out according to the same reaction conditions as in Step A-3.
- Step F-1 The compound (37) can be obtained by a condensation reaction of the compound (36) and the compound (2).
- the reaction in Step F-1 can be carried out according to the same reaction conditions as in Step A-1.
- Step F-2 The compound (39) can be obtained by an oxadiazole cyclization reaction after an amide oximation reaction of the compound (37).
- the nitrile (37) is first converted into an amide oxime by treatment with an alcohol solvent such as methanol or ethanol, hydroxylamine (25) or a hydrochloride thereof, and then tetrahydrofuran or 1,4- Ether solvents such as dioxane, aprotic polar solvents such as N, N-dimethylformamide, halogen solvents such as dichloromethane and chloroform, aromatic hydrocarbon solvents such as toluene, ethyl acetate, acetonitrile, or a mixed solvent thereof Among them, the reaction can be carried out under the conditions of reacting with a dehydrating condensing agent such as carboxylic acid (38) and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide / hydroch
- Step G-1 The compound (41) can be obtained by a condensation reaction of the compound (40) and the compound (2). The reaction in Step G-1 can be carried out according to the same reaction conditions as in Step A-1.
- Step G-2 The compound (42) can be obtained by a coupling reaction of the compound (41) and the compound (4). The reaction in Step G-2 can be carried out according to the same reaction conditions as in Step A-2.
- Step G-3 The compound (If) of the present invention can be obtained by an alkylation reaction of the compound (42). The reaction in Step G-3 can be carried out according to the same reaction conditions as in Step A-3.
- Scheme H The compound (If) of the present invention can be obtained by an alkylation reaction of the compound (42). The reaction in Step G-3 can be carried out according to the same reaction conditions as in Step A-3.
- Step H-1 Compound (43) can be obtained by deprotection of Compound (20). The reaction in Step H-1 can be carried out according to the same reaction conditions as in Step C-9.
- Step H-2 The compound (45) can be obtained by a condensation reaction of the compound (43) and the compound (44). The reaction in Step H-2 can be carried out according to the same reaction conditions as in Step A-1.
- Step H-3 The compound (Ig) of the present invention can be obtained by an alkylation reaction of the compound (45). The reaction in Step H-3 can be carried out according to the same reaction conditions as in Step A-3.
- Step I-1 Compound (47) can be obtained by Horner-Wadsworth-Emmons reaction of compound (46). The reaction in Step I-1 can be carried out according to the same reaction conditions as in Step C-4.
- Step I-2 The compound (48) can be obtained by the reduction reaction of the double bond of the compound (47). The reaction in Step I-2 can be carried out according to the same reaction conditions as in Step C-5.
- Step I-3 Compound (49) can be obtained by hydrolysis of compound (48). The reaction in step I-3 can be carried out according to the same reaction conditions as in step B-2.
- Step I-4 Compound (50) can be obtained from compound (49) by a reaction via Curtius rearrangement. The reaction in Step I-4 can be carried out according to the same reaction conditions as in Step C-7.
- Step I-5 Compound (51) can be obtained by deprotection of Compound (50). The reaction in Step I-5 can be carried out according to the same reaction conditions as in Step C-9.
- Step I-6 Compound (52) can be obtained by the condensation reaction of compound (51) and compound (44). The reaction in Step I-6 can be carried out according to the same reaction conditions as in Step A-1.
- Step I-7 Compound (53) can be obtained by alkylation reaction of compound (52). The reaction in Step I-7 can be carried out according to the same reaction conditions as in Step A-3.
- Step I-8 Compound (54) can be obtained by deprotection of Compound (53).
- Step I-8 The reaction in Step I-8 is carried out in an alcohol solvent such as methanol or ethanol, an ether solvent such as tetrahydrofuran or 1,4-dioxane, a halogen solvent such as dichloromethane or chloroform, water or a mixed solvent thereof, hydrochloric acid, trifluoro
- the treatment can be carried out under conditions of treatment with acetic acid or the like. In addition, this reaction can be performed at 0 ° C. to 100 ° C.
- Step I-9 The compound (IH) of the present invention can be obtained by a coupling reaction of the compound (54) and the compound (55).
- the reaction in Step I-9 can be carried out according to the same reaction conditions as in Step A-2.
- Step J-1 The compound (56) can be obtained by a condensation reaction of the compound (36) and the compound (44). The reaction in Step J-1 can be carried out according to the same reaction conditions as in Step A-1.
- Step J-2 The compound (58) can be obtained by an oxadiazole cyclization reaction after an amide oximation reaction of the compound (56). The reaction in Step J-2 can be carried out according to the same reaction conditions as in Step F-2.
- Step J-3 The compound (II) of the present invention can be obtained by the alkylation reaction of the compound (58). The reaction in Step J-3 can be carried out according to the same reaction conditions as in Step A-3.
- Step K-1 The compound (60) can be obtained by the alkylation reaction of the compound (59). The reaction in step K-1 can be carried out according to the same reaction conditions as in step A-3.
- Step K-2 Compound (61) can be obtained by oxadiazole cyclization after amide oximation of compound (60). The reaction in step K-2 can be carried out according to the same reaction conditions as in step F-2.
- Step K-3 Compound (62) can be obtained by deprotection of compound (61). The reaction in Step K-3 can be carried out according to the same reaction conditions as in deprotection under the acidic conditions in Step C-9.
- Step K-4 The compound (II) of the present invention can be obtained by the condensation reaction of the compound (62) and the compound (44). The reaction in Step K-4 can be carried out according to the same reaction conditions as in Step A-1.
- Step L-1 Compound (61) can be obtained by oxadiazole cyclization reaction after amide oximation reaction of compound (60).
- the nitrile body (60) is first converted into an amide oxime by treatment with an alcohol solvent such as methanol or ethanol, hydroxylamine (25) or a hydrochloride thereof, and then N, N-dimethylformamide.
- an alcohol solvent such as methanol or ethanol, hydroxylamine (25) or a hydrochloride thereof
- N, N-dimethylformamide In a non-protic polar solvent such as p-toluenesulfonic acid monohydrate and zinc chloride in the presence of benzonitrile (63). This reaction can be carried out at 80 ° C. to 120 ° C.
- KP-Sil when purified using column chromatography is “Biotage SNAPPartridge KP-Sil”, “HP-Sil” is Biotage SNAPPartridge HP-Sil, “KP-Sil”.
- Biotage SNAP Cartridge KP-NH was used.
- Biotage's ISOLUTE Phase Separator was used for “ISOLUTE Phase Separator” in the post-processing operations of the following Reference Examples and Examples.
- LCMS liquid chromatography mass spectrum
- MS measuring instrument SHIMADZU LCMS-2010EV or micromass Platform LC
- Ethyl-2- (diethoxyphosphoryl) acetate (0.163 mL, 0.816 mmol) was added to a THF suspension (1.3 mL) of 60% NaH (0.033 g, 0.82 mmol) under ice-cooling. For 5 minutes.
- To a suspension of 1- (5-fluoropyridin-2-yl) -1H-pyrazole-3-carbaldehyde (0.130 g, 0.680 mmol) obtained in Reference Example 13 in THF (1.3 mL) was added the above.
- the mixture and THF (0.65 mL) were added under ice cooling, and the mixture was stirred at room temperature for 1.5 hours.
- N-[(3E) -3- (hydroxyimino) propyl] -5-methyl-2- (2H-1,2,3-triazol-2-yl) benzamide (0.45 g, obtained in Reference Example 20 1.6 mmol) in DMF (5 mL) was added N-chlorosuccinimide (0.24 g, 1.8 mmol) in an ice bath, and the mixture was warmed to room temperature and stirred for 15 hours. Water was added to the reaction solution, and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na 2 SO 4 , the desiccant was filtered off, and the solvent was distilled off under reduced pressure.
- a DMF solution (0.3 mL) of the obtained residue was stirred at 40 ° C. for 1 hour, and 5-fluoropyridine-2-carboxylic acid (0.12 g, 0.82 mmol) and carbonyldiimidazole (0.15 g, 0.8%). 94 mmol) in DMF (0.5 mL).
- the reaction solution was heated to 90 ° C. and stirred for 15 hours.
- Water was added to the reaction mixture and extracted with EtOAc. The organic layer was washed with water and brine, dried over Na 2 SO 4 , the desiccant was filtered off, and the solvent was distilled off under reduced pressure.
- Reference Examples 34 to 37 were obtained in the same manner as Reference Example 33.
- Table 1 shows the structural formula, compound name, and MS data of the obtained compound.
- Reference examples 43 and 44 were obtained in the same manner as in reference example 42.
- Table 2 shows the structural formula, compound name, and MS data of the obtained compound.
- Reference Examples 46 and 47 were obtained in the same manner as Reference Example 45.
- Table 3 shows the structural formula, compound name, and MS data of the obtained compound.
- Reference Examples 49 and 50 were obtained in the same manner as Reference Example 48.
- Table 4 shows the structural formula, compound name, and MS data of the obtained compound.
- Reference Examples 53 to 56 were obtained in the same manner as Reference Example 52.
- Table 5 shows the structural formula, compound name, and MS data of the obtained compound.
- a 50% aqueous hydroxylamine solution (2.0 mL) was added to an ethanol solution (20 mL) of tert-butyl (2-cyanoethyl) ethylcarbamate (4.70 g, 23.7 mmol) obtained in Reference Example 57 at 90 ° C. Stir for 5 hours. After allowing to cool at room temperature, the solvent of the reaction solution was distilled off under reduced pressure. Saturated aqueous sodium chloride solution was added to the obtained residue, and the mixture was extracted with chloroform, passed through a phase separator, and the solvent was distilled off under reduced pressure.
- Reference Example 60 was obtained in the same manner as Reference Example 59.
- Table 6 shows the structural formula, compound name, and MS data of the obtained compound.
- Reference Examples 62 and 63 were obtained in the same manner as Reference Example 61.
- Table 7 shows the structural formula, compound name, and MS data of the obtained compound.
- N-ethyl-2- [1- (5-fluoropyridin-2-yl) -1H-pyrazol-3-yl] ethanamine hydrochloride (0.028 g, 0.10 mmol) obtained in Reference Example 18 in CHCl 3
- Et 3 N (0.017 mL, 0.12 mmol)
- 5-fluoro-2- (2H-1,2,3-triazol-2-yl) benzoic acid (0.032 g,. 15 mmol)
- HOBt ⁇ H 2 O 0.19 g, 0.12 mmol
- EDC ⁇ HCl 0.024 g, 0.12 mmol
- Examples 18 to 21 were obtained in the same manner as in Example 17.
- Table 8 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 23 to 30 were obtained in the same manner as in Example 22.
- Table 9 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 32 to 37 were obtained in the same manner as in Example 31.
- Table 10 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Examples 39 to 46 were obtained in the same manner as in Example 38.
- Table 11 shows the structural formula, compound name, and LCMS data of the obtained compound.
- Test example (measurement of orexin antagonistic activity)
- the antagonistic activity of test compounds against human orexin type 1 receptor (hOX1R) and orexin type 2 receptor (hOX2R) was described in the literature (Toshikatsu Okumura et al., Biochemical and Biophysical Research Communications 280, 976-981, 2001). The method was modified. Chinese hamster ovary (CHO) cells in which hOX1R and hOX2R are forcibly expressed were seeded in each well of a 96-well Black clear bottom plate (Nunc) at 20,000 cells, 0.1 mM MEM non-essential amino acids, 0.
- CHO Chinese hamster ovary
- the cells were cultured in Ham's F-12 medium (Invitrogen) containing 5 mg / mL G418, 10% fetal calf serum for 16 hours under conditions of 37 ° C. and 5% CO 2 .
- an assay buffer containing 25 ⁇ M Fluo-4AM ester (Dojin) (25 mM HEPES (Dojin), Hanks' balanced salt solution (Invitrogen), 0.1% bovine serum albumin, 2.5 mM probenecid, 100 ⁇ L of 200 ⁇ g / mL Amaranth (above Sigma-Aldrich), pH 7.4) was added and incubated for 60 minutes at 37 ° C., 5% CO 2 .
- test compound was dissolved in dimethyl sulfoxide to 10 mM, diluted with assay buffer, 150 ⁇ L was added, and the mixture was incubated for 30 minutes.
- Peptide substituted with 2 amino acids of human orexin-A ligand (Pyr-Pro-Leu-Pro-Asp-Ala-Cys-Arg-Gln-Lys-Thr-Ala-Ser-Cys-Arg-Leu-Tyr-Glu -Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (Peptide Institute) is a final concentration of 300 pM for hOX1R and hOX2R Each was diluted with an assay buffer so as to be 3 nM, and 50 ⁇ L of this ligand solution was added to initiate the reaction.
- the fluorescence value of each well was measured for 3 minutes every second using a Functional Drug Screening System (FDSS; manufactured by Hamamatsu Photonics), and the antagonistic activity was determined using the maximum fluorescence value as an indicator of intracellular Ca 2+ concentration.
- the antagonistic activity of the test compound was calculated by setting the fluorescence value of the well to which only the dilution buffer was added to 100% and the fluorescence value of the well to which the buffer solution containing no ligand and compound was added to 0%.
- the 50% inhibitory concentration (IC 50 value) was determined from the fluorescence value upon addition.
- the IC 50 values of the compounds of the present invention are shown in Table 12.
- the compound of the present invention was shown to have an OX receptor antagonistic action. Therefore, the compound of the present invention or a pharmaceutically acceptable salt thereof is a disease modulated by OX receptor antagonism, such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease It can be used as a therapeutic or prophylactic agent for Parkinson's disease, Huntington's chorea, eating disorders, pain, digestive disorders, epilepsy, inflammation, immune related diseases, endocrine related diseases, hypertension and the like.
- OX receptor antagonism such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease It can be used as a therapeutic or prophylactic agent for Parkinson's disease, Huntington's chorea, eating disorders, pain, digestive disorders, epilepsy, inflammation, immune related diseases, endocrine related diseases, hypertension and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
OX受容体のサブタイプによって組織分布は異なっており、OX1受容体はノルアドレナリン作動性神経の起始核である青斑核、OX2受容体はヒスタミン神経の起始核である結節乳頭核に高密度に発現している(非特許文献3、非特許文献4及び非特許文献5参照)。セロトニン神経の起始核である縫線核や、ドパミン神経の起始核である腹側被蓋野にはOX1受容体とOX2受容体両方の発現がみられる(非特許文献3参照)。オレキシン神経は脳幹と視床下部のモノアミン神経系に投射し、それらの神経に対して興奮性の影響を与えており、さらにREM睡眠の制御に関わる脳幹のアセチルコリン神経にもOX2受容体の発現がみられ、これらの神経核の活性にも影響を及ぼしている(非特許文献3及び非特許文献4参照)。
OX受容体拮抗作用化合物としては、例えば総説として非特許文献11に記載の種々の構造を有する化合物が知られている。
すなわち本発明は、
(1)式(IA)
Xは、窒素原子、又は式CHを示し、
Yは下記式群(II)のいずれかを示し、
R2は、水素原子、C1-6アルキル基(ここで、該C1-6アルキル基は、置換基群1から選ばれる1~3個の置換基で置換されてもよい)、C3-6シクロアルキル基、又は4-6員の環状エーテル基を示し、
置換基群1は、ハロゲン原子、C3-6シクロアルキル基、及びC1-6アルコキシ基からなる群であり、
R3は、トリアゾリル基、ピリジル基、又はピリミジニル基を示し、
該トリアゾリル基、ピリジル基及びピリミジニル基は、1~3個のハロゲン原子で置換されてもよく、
R4及びR5は、同一又は異なって水素原子、ハロゲン原子、又はC1-6アルキル基(該C1-6アルキル基は、1~3個のハロゲン原子で置換されてもよい)を示す)
で表されるヘテロ芳香環誘導体、又はその医薬上許容される塩、
(2)R4が、ハロゲン原子であり、
R5が、水素原子又はハロゲン原子である(1)に記載のヘテロ芳香環誘導体、又はその医薬上許容される塩、
(3)式(I)
Xは、窒素原子、又は式CHを示し、
Yは下記式群(II)のいずれかを示し、
R2は、水素原子、C1-6アルキル基(該C1-6アルキル基は、置換基群1から選ばれる1~3個の置換基で置換されてもよい)、C3-6シクロアルキル基、又は4-6員の環状エーテル基を示し、
置換基群1は、ハロゲン原子、C3-6シクロアルキル基、及びC1-6アルコキシ基からなる群であり、
R3は、トリアゾリル基、ピリジル基、又はピリミジニル基を示し、
該トリアゾリル基、ピリジル基及びピリミジニル基は、1~3個のハロゲン原子で置換されてもよく、
R4は、水素原子、ハロゲン原子、又はC1-6アルキル基を示す)
で表されるヘテロ芳香環誘導体、又はその医薬上許容される塩、
R2が、C1-6アルキル基であり、
R3が、トリアゾリル基、又はピリミジニル基であり、
R4が、ハロゲン原子である(1)~(3)のいずれか1つに記載のヘテロ芳香環誘導体、又はその医薬上許容される塩、
(5)R2が、メチル基、又はエチル基である(1)~(4)のいずれか1つに記載のヘテロ芳香環誘導体、又はその医薬上許容される塩、
(6)上記(1)~(5)のいずれか1つに記載のヘテロ芳香環誘導体、又はその医薬上許容される塩を有効成分として含有する医薬組成物、及び
(7)上記(1)~(5)のいずれか1つに記載のヘテロ芳香環誘導体、又はその医薬上許容される塩を有効成分として含有することを特徴とする、睡眠障害、うつ病、不安障害、パニック障害、統合失調症、薬物依存症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、疼痛、消化器疾患、てんかん、炎症、免疫関連疾患、内分泌関連疾患、又は高血圧等の疾患の治療又は予防薬である。
「ハロゲン原子」とは、フッ素原子、塩素原子、臭素原子、ヨウ素原子である。
「C1-6アルキル基」とは、直鎖状又は分岐鎖状の炭素数1~6個のアルキル基を意味し、例えばメチル、エチル、n-プロピル、イソプロピル、n-ブチル、イソブチル、sec-ブチル、tert-ブチル、n-ペンチル、イソペンチル、ネオペンチル、tert-ペンチル、1-エチルプロピル、n-ヘキシル、イソヘキシル、ネオヘキシル基等を挙げることができる。
「C3-6シクロアルキル基」とは、シクロプロピル、シクロブチル、シクロペンチル、シクロヘキシル基である。
「4-6員の環状エーテル基」とは、オキセタニル、テトラヒドロフラニル、テトラヒドロピラニル基である。
「C1-6アルコキシ基」とは直鎖状又は分岐鎖状の炭素数1~6個のアルコキシ基を意味し、例えばメトキシ、エトキシ、n-プロポキシ、イソプロポキシ、n-ブトキシ、イソブトキシ、sec-ブトキシ、tert-ブトキシ、n-ペンチルオキシ、イソペンチルオキシ、ネオペンチルオキシ、tert-ペンチルオキシ、1-エチルプロポキシ、n-ヘキシルオキシ基等を挙げることができる。
Xは、窒素原子である化合物が好ましい。
Yは、下記式群(IIa)のいずれかである化合物が好ましい。
R2は、C1-6アルキル基である化合物が好ましく、メチル基又はエチル基である化合物がより好ましい。
R3は、トリアゾリル基又はピリミジニル基である化合物が好ましく、1,2,3-トリアゾール-2-イル基又はピリミジン-2-イル基がより好ましい。
R4は、ハロゲン原子である化合物が好ましく、ヨウ素以外の化合物がより好ましく、フッ素原子又は塩素原子である化合物がさらに好ましく、フッ素原子である化合物が最も好ましい。
R5は、水素原子又はハロゲン原子である化合物が好ましく、水素原子又はフッ素原子である化合物がより好ましい。
本発明化合物中の好ましい化合物の例として、
N-エチル-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-4-イル]エチル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-4-イル]エチル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-4-イル]エチル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-5-フルオロ-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[3-(5-フルオロピリジン-2-イル)-1,2-オキサゾール-5-イル]エチル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[3-(5-フルオロピリジン-2-イル)-1,2,4-オキサジアゾール-5-イル]エチル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
5-クロロ-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-N-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-4-フルオロ-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-2-フルオロ-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-2-フルオロ-N-{2-[1-(5-フルオロピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-6-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(4-フルオロフェニル)-1H-ピラゾール-3-イル]エチル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(6-メチルピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-2-(2H-1,2,3-トリアゾール-2-イル)-N-(2-{1-[6-(トリフルオロメチル)ピリジン-2-イル]-1H-ピラゾール-3-イル}エチル)ベンズアミド、
N-{2-[1-(3,4-ジフルオロフェニル)-1H-ピラゾール-3-イル]エチル}-N-エチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{2-[1-(4-フルオロフェニル)-1H-ピラゾール-3-イル]エチル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{2-[1-(6-メチルピリジン-2-イル)-1H-ピラゾール-3-イル]エチル}-2-(ピリミジン-2-イル)ベンズアミド、
N-{2-[1-(3,4-ジフルオロフェニル)-1H-ピラゾール-3-イル]エチル}-N-エチル-5-フルオロ-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{2-[1-(4-フルオロフェニル)-1H-ピラゾール-3-イル]エチル}-2-(ピリミジン-2-イル)ベンズアミド、
N-{2-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]エチル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-{2-[5-(3,4-ジフルオロフェニル)-1,2,4-オキサジアゾール-3-イル]エチル}-N,5-ジメチル-2-(2H-1,2,3-トリアゾール-3-イル)ベンズアミド、
N-エチル-N-{2-[5-(3,4-ジフルオロフェニル)-1,2,4-オキサジアゾール-3-イル]エチル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]エチル}-5-メチル-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
N-エチル-N-{2-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]エチル}-5-メチル-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-5-フルオロ-N-{2-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]エチル}-2-(ピリミジン-2-イル)ベンズアミド、
N-エチル-N-{2-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]エチル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、及び、
N-エチル-N-{2-[5-(3,4-ジフルオロフェニル)-1,2,4-オキサジアゾール-3-イル]エチル}-2-(2H-1,2,3-トリアゾール-2-イル)ベンズアミド、
が挙げられる。
なお、本発明化合物が水和物又は溶媒和物を形成する場合、それらも本発明の範囲内に含まれる。同様に、本発明化合物の水和物又は溶媒和物の医薬上許容される塩も本発明の範囲内に含まれる。
本発明に係る化合物には、一つ以上の水素原子、炭素原子、窒素原子、酸素原子、フッ素原子が放射性同位元素や安定同位元素と置換された化合物も含まれる。これらの標識化合物は、代謝や薬物動態研究、受容体のリガンド等として生物学的分析等に有用である。
本発明に係る化合物は、経口又は非経口的に投与することができる。その投与剤型は錠剤、カプセル剤、顆粒剤、散剤、粉剤、トローチ剤、軟膏剤、クリーム剤、皮膚貼付剤、乳剤、懸濁剤、坐剤、注射剤等であり、いずれも慣用の製剤技術(例えば、第15改正日本薬局方に規定する方法等)によって製造することができる。これらの投与剤型は、患者の症状、年齢、体重、及び治療の目的に応じて適宜選択することができる。
これらの製剤は、本発明の化合物を含有する組成物に薬理学的に許容されるキャリヤー、すなわち、賦形剤(例えば、結晶セルロース、デンプン、乳糖、マンニトール)、結合剤(例えば、ヒドロキシプロピルセルロース、ポリビニルピロリドン)、滑沢剤(例えば、ステアリン酸マグネシウム、タルク)、崩壊剤(例えば、カルボキシメチルセルロースカルシウム)、その他薬理学的に許容される各種添加剤を配合し、製造することができる。
本発明の化合物は、成人患者に対して1回の投与量として0.001~500mgを1日1回又は数回に分けて経口又は非経口で投与することが可能である。なお、この投与量は治療対象となる疾病の種類、患者の年齢、体重、症状等により適宜増減することができる。
スキームA
スキームB
本発明化合物(I‐b)はスキームBに示す方法で製造することができる。
スキームC
本発明化合物(I‐b)は別法としてスキームCに示す方法でも製造することができる。
工程C-6:化合物(19)は、化合物(18)の加水分解反応により得ることができる。工程C-6における反応は工程B-2と同様の反応条件に従って行うことができる。
工程C-8:化合物(21)は、化合物(20)のアルキル化反応により得ることができる。工程C-8における反応は工程A-3と同様の反応条件に従って実施できる。
工程C-10:本発明化合物(I‐b)は、化合物(13)と化合物(2)の縮合反応により得ることができる。工程C-10における反応は工程A-1と同様の反応条件に従って実施できる。
スキームD
工程D-1:化合物(23)は、化合物(22)と化合物(2)の縮合反応により得ることができる。工程D-1における反応は工程A-1と同様の反応条件に従って実施できる。
スキームE
工程E-1:化合物(31)は、化合物(30)とヒドロキシルアミン(25)の縮合反応により得ることができる。工程E-1における反応は工程D-3と同様の反応条件に従って実施できる。
工程E-2:化合物(33)は、化合物(31)のハロゲン化反応の後、イソオキサゾール環化反応により得ることができる。工程E-2における反応は工程D-4と同様の反応条件に従って実施できる。
工程E-4:化合物(35)は、化合物(34)と化合物(2)の縮合反応により得ることができる。工程E-4における反応は工程A-1と同様の反応条件に従って実施できる。
工程E-5:本発明化合物(I‐d)は、化合物(35)のアルキル化反応により得ることができる。工程E-5における反応は工程A-3と同様の反応条件に従って実施できる。
スキームF
工程F-1:化合物(37)は、化合物(36)と化合物(2)の縮合反応により得ることができる。工程F-1における反応は工程A-1と同様の反応条件に従って実施できる。
工程F-3:本発明化合物(I‐e)は、化合物(39)のアルキル化反応により得ることができる。工程F-3における反応は工程A-3と同様の反応条件に従って実施できる。
スキームG
工程G-1:化合物(41)は、化合物(40)と化合物(2)の縮合反応により得ることができる。工程G-1における反応は工程A-1と同様の反応条件に従って実施できる。
工程G-2:化合物(42)は、化合物(41)と化合物(4)のカップリング反応により得ることができる。工程G-2における反応は工程A-2と同様の反応条件に従って実施できる。
工程G-3:本発明化合物(I‐f)は、化合物(42)のアルキル化反応により得ることができる。工程G-3における反応は工程A-3と同様の反応条件に従って実施できる。
スキームH
工程H-1:化合物(43)は、化合物(20)の脱保護により得ることができる。工程H-1における反応は工程C-9と同様の反応条件に従って実施できる。
工程H-2:化合物(45)は、化合物(43)と化合物(44)の縮合反応により得ることができる。工程H-2における反応は工程A-1と同様の反応条件に従って実施できる。
工程H-3:本発明化合物(I‐g)は、化合物(45)のアルキル化反応により得ることができる。工程H-3における反応は工程A-3と同様の反応条件に従って実施できる。
スキームI
工程I-1:化合物(47)は、化合物(46)のホーナー‐ワズワース‐エモンズ反応により得ることができる。工程I-1における反応は工程C-4と同様の反応条件に従って実施できる。
工程I-2:化合物(48)は、化合物(47)の二重結合の還元反応により得ることができる。工程I-2における反応は工程C-5と同様の反応条件に従って実施できる。
工程I-3:化合物(49)は、化合物(48)の加水分解反応により得ることができる。工程I-3における反応は工程B-2と同様の反応条件に従って実施できる。
工程I-4:化合物(50)は、化合物(49)からクルチウス転位を経由した反応により得ることができる。工程I-4における反応は工程C-7と同様の反応条件に従って実施できる。
工程I-6:化合物(52)は、化合物(51)と化合物(44)の縮合反応により得ることができる。工程I-6における反応は工程A-1と同様の反応条件に従って実施できる。
工程I-7:化合物(53)は、化合物(52)のアルキル化反応により得ることができる。工程I-7における反応は工程A-3と同様の反応条件に従って実施できる。
工程I-8:化合物(54)は、化合物(53)の脱保護により得ることができる。工程I-8における反応はメタノール、エタノール等のアルコール系溶媒、テトラヒドロフランや1,4-ジオキサン等のエーテル系溶媒、ジクロロメタン、クロロホルム等のハロゲン系溶媒、水又はそれらの混合溶媒中、塩酸、トリフルオロ酢酸等で処理する条件で実施できる。また、本反応は0℃~100℃で行うことができる。
工程I-9:本発明化合物(I‐H)は、化合物(54)と化合物(55)のカップリング反応により得ることができる。工程I-9における反応は工程A-2と同様の反応条件に従って実施できる。
スキームJ
工程J-1:化合物(56)は、化合物(36)と化合物(44)の縮合反応により得ることができる。工程J-1における反応は工程A-1と同様の反応条件に従って実施できる。
工程J-2:化合物(58)は、化合物(56)のアミドオキシム化反応の後、オキサジアゾール環化反応により得ることができる。工程J-2における反応は工程F-2と同様の反応条件に従って実施できる。
工程J-3:本発明化合物(I‐I)は化合物(58)のアルキル化反応により得ることができる。工程J-3における反応は工程A-3と同様の反応条件に従って実施できる。
スキームK
本発明化合物(I‐I)は別法としてスキームKに示す方法でも製造することができる。
工程K-1:化合物(60)は化合物(59)のアルキル化反応により得ることができる。工程K-1における反応は工程A-3と同様の反応条件に従って実施できる。
工程K-2:化合物(61)は化合物(60)のアミドオキシム化反応の後、オキサジアゾール環化反応により得ることができる。工程K-2における反応は工程F-2と同様の反応条件に従って実施できる。
工程K-3:化合物(62)は化合物(61)の脱保護反応により得ることができる。工程K-3における反応は工程C-9の酸性条件での脱保護と同様の反応条件に従って実施できる。
工程K-4:本発明化合物(I‐I)は化合物(62)と化合物(44)の縮合反応により得ることができる。工程K-4における反応は工程A-1と同様の反応条件に従って実施できる。
スキームL
化合物(61)は別法としてスキームLに示す方法でも製造することができる。
工程L-1:化合物(61)は化合物(60)のアミドオキシム化反応の後、オキサジアゾール環化反応により得ることができる。工程L-1における反応は最初にニトリル体(60)をメタノール、エタノール等のアルコール系溶媒、ヒドロキシルアミン(25)又はその塩酸塩で処理することでアミドオキシム化した後、N,N-ジメチルホルムアミド等の非プロトン性極性溶媒中、p-トルエンスルホン酸1水和物、塩化亜鉛存在下、ベンゾニトリル(63)と反応させる条件で実施できる。本反応は80℃~120℃で行うことができる。
以下の参考例及び実施例の後処理操作の際の「ISOLUTE Phase Separator」にはBiotage社ISOLUTE Phase Separatorを使用した。
条件1
機械:Gilson社 preparative HPLC system
カラム:資生堂 Capcell Pak C18 MGII 5μm 20x150mm
溶媒:A液;0.1%トリフルオロ酢酸含有水、B液;0.1%トリフルオロ酢酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、22分(A液/B液=20/80)、25分(A液/B液=10/90)
流速:20mL/min、検出法:UV 254nm
機械:Gilson社 TrilutionLC
カラム:Waters社 SunFire prep C18 OBD 5.0μm 30x50mm 又はYMC社 YMC-Actus Triant C18 5.0μm 30x50mm
溶媒:A液;0.1%トリフルオロ酢酸含有水、B液;0.1%トリフルオロ酢酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、11分(A液/B液=20/80)、12~13.5分(A液/B液=5/95)
流速:40mL/min、検出法:UV 254nm
条件1
測定機械:MicroMass社 Platform LCおよびAgilent社 Agilent1100
カラム:Waters社 SunFire C18 2.5μm 4.6mmI.D.x50mm
溶媒:A液;0.1%トリフルオロ酢酸含有水、B液;0.1%トリフルオロ酢酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、0.5分(A液/B液=90/10)、5.5分(A液/B液=20/80)、6.0分(A液/B液=1/99)、6.3分(A液/B液=1/99)
流速:1mL/min、検出法:UV 254nm
イオン化法:エレクトロンスプレー法(ESI:Electron Spray Ionization)
測定機械:SHIMADZU社 LCMS-2010EV
カラム:SHIMADZU社 Shim-pack XR-ODS 2.2μm 2.0mmI.D.x30mm
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、1分(A液/B液=60/40)、2分(A液/B液=0/100)、2.5分(A液/B液=0/100)
流速:0.6mL/min、検出法:UV 254nm
イオン化法:エレクトロンスプレー法(ESI:Electron Spray Ionization)及び大気圧化学イオン法(APCI:Atomospheric Pressure Chemical Ionization)
測定機械:Agilent社 Agilent2900及びAgilent6150
カラム:Waters社 Acquity CSH C18 1.7μm 2.1x50mm
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
グラジエント:0分(A液/B液=80/20)、1.2~1.4分(A液/B液=1/99)
流速:0.8mL/min、検出法:UV 254nm
イオン化法:エレクトロンスプレー法(ESI:Electron Spray Ionization)
MS測定機器:SHIMADZU社 LCMS-2010EVあるいはmicromass社 Platform LC
Na2SO4(無水硫酸ナトリウム)、NaHCO3(炭酸水素ナトリウム)、NaOH(水酸化ナトリウム)、NH4Cl(塩化アンモニウム)、MeOH(メタノール)、EtOH(エタノール)、Et2O(ジエチルエーテル)、THF(テトラヒドロフラン)、DMF(N,N-ジメチルホルムアミド)、MeCN(アセトニトリル)、EtOAc(酢酸エチル)、CHCl3(クロロホルム)、HOBt・H2O(1-ヒドロキシベンゾトリアゾール・一水和物)、EDC・HCl[1-(3-ジメチルアミノプロピル)-3-エチルカルボジイミド・一塩酸塩]、HATU[O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロホスファート]、brine(飽和食塩水)、Boc(tert-ブトキシカルボニル)、Et3N(トリエチルアミン)、DIPEA(N,N-ジイソプロピルエチルアミン)、MeI(ヨウ化メチル)、EtI(ヨウ化エチル)、NaH(水素化ナトリウム)、HCl(塩化水素)、DIBAL-H(水素化ジイソブチルアルミニウム)、MnO2(二酸化マンガン)。
MS (ESI pos.) m/z : 297 [M+H]+
MS (ESI pos.) m/z : 283 [M+H]+
MS (ESI pos.) m/z : 392 [M+H]+
MS (ESI pos.) m/z : 378 [M+H]+
MS (ESI pos.) m/z : 236 [M+H]+
MS (ESI pos.) m/z : 206 [M-H]-
MS (ESI pos.) m/z : 220 [M-H]-
MS (ESI pos.) m/z : 249 [M+H]+
MS (ESI pos.) m/z : 235 [M+H]+
MS (ESI pos.) m/z : 235 [M+H]+
MS (ESI pos.) m/z : 221 [M+H]+
MS (ESI/APCI pos.) m/z : 194 [M+H]+
MS (ESI pos.) m/z : 192 [M+H]+
MS (ESI pos.) m/z : 262 [M+H]+
MS (ESI/APCI pos.) m/z : 258 [M+Na]+
MS (ESI/APCI pos.) m/z : 329 [M+Na]+
MS (ESI/APCI pos.) m/z : 335 [M+H]+
MS (ESI/APCI pos.) m/z : 235 [M+H]+
MS (ESI pos.) m/z : 333 [M+H]+
MS (ESI pos.) m/z : 274 [M+H]+
MS (ESI pos.) m/z : 393 [M+H]+
MS (ESI pos.) m/z : 141 [M+H]+
MS (ESI pos.) m/z : 338 [M+H]+
MS (ESI pos.) m/z : 208 [M+H]+
MS (ESI pos.) m/z : 393 [M+H]+
MS (ESI pos.) m/z : 256 [M+H]+
MS (ESI pos.) m/z : 394 [M+H]+
MS (ESI pos.) m/z : 297 [M+H]+
MS (ESI pos.) m/z : 392 [M+H]+
MS (ESI pos.) m/z : 321 [M+H]+
MS (ESI pos.) m/z : 221 [M+H]+
MS (ESI pos.) m/z : 207 [M+H]+
MS (ESI pos.) m/z : 396 [M+H]+
MS (ESI pos.) m/z : 251 [M+H]+
MS (ESI pos.) m/z : 247 [M+Na]+
MS (ESI pos.) m/z : 352 [M+Na]+
MS (ESI pos.) m/z : 196 [M+H]+
MS (ESI pos.) m/z : 367 [M+H]+
MS (ESI pos.) m/z : 395 [M+H]+
MS (ESI pos.) m/z : 311 [M+H]+
MS (ESI pos.) m/z : 242 [M+H]+
MS (ESI pos.) m/z : 380 [M+H]+
MS (ESI pos.) m/z : 199 [M+H]+
MS (ESI pos.) m/z : 336 [M+H]+
MS (ESI pos.) m/z : 376 [M+Na]+
MS (ESI pos.) m/z : 254 [M+H]+
LCMS retention time 5.70 min.(条件1)
MS (ESI pos.) m/z : 420 [M+H]+
LCMS retention time 5.39 min. (条件1)
MS (ESI pos.) m/z : 406 [M+H]+
LCMS retention time 5.41 min. (条件1)
MS (ESI pos.) m/z : 406 [M+H]+
LCMS retention time 5.54 min. (条件1)
MS (ESI pos.) m/z : 406 [M+H]+
LCMS retention time 5.50 min. (条件1)
MS (ESI pos.) m/z : 406 [M+H]+
LCMS retention time 1.83 min. (条件2)
MS (ESI/APCI pos.) m/z : 431 [M+H]+
LCMS retention time 1.83 min. (条件2)
MS (ESI/APCI pos.) m/z : 424 [M+H]+
LCMS retention time 1.88 min. (条件2)
MS (ESI/APCI pos.) m/z : 420 [M+H]+
LCMS retention time 5.11 min. (条件1)
MS (ESI pos.) m/z : 407 [M+H]+
LCMS retention time 5.42 min. (条件1)
MS (ESI pos.) m/z : 421 [M+H]+
LCMS retention time 5.56 min. (条件1)
MS (ESI pos.) m/z : 421 [M+H]+
LCMS retention time 5.19 min. (条件1)
MS (ESI pos.) m/z : 422 [M+H]+
LCMS retention time 3.56 min. (条件1)
MS (ESI pos.) m/z : 420 [M+H]+
LCMS retention time 1.74 min. (条件2)
MS (ESI pos.) m/z : 392 [M+H]+
LCMS retention time 1.79 min. (条件2)
MS (ESI pos.) m/z : 410 [M+H]+
LCMS retention time 1.82 min. (条件2)
MS (ESI pos.) m/z : 426 [M+H]+
LCMS retention time 1.04 min.(条件3)
MS (ESI pos.) m/z : 424 [M+H]+
LCMS retention time 1.01 min.(条件3)
MS (ESI pos.) m/z : 405 [M+H]+
LCMS retention time 0.95 min.(条件3)
MS (ESI pos.) m/z : 393 [M+H]+
LCMS retention time 1.07 min.(条件3)
MS (ESI pos.) m/z : 421 [M+H]+
試験化合物のヒトオレキシン1型受容体(hOX1R)、オレキシン2型受容体(hOX2R)に対する拮抗活性は文献(Toshikatsu Okumura et al., Biochemical and Biophysical Research Communications 280, 976-981, 2001)に記載された方法を改変して行った。hOX1R、hOX2Rを強制発現させたChinese hamster ovary(CHO)細胞を96wellのBlack clear bottomプレート(Nunc)の各ウェルに20,000個となるように播種し、0.1mM MEM非必須アミノ酸、0.5mg/mL G418、10% 牛胎児血清を含むHam’s F-12培地(以上インビトロジェン)で、37℃、5% CO2の条件下で16時間培養した。培地を除去後、0.5μM Fluo-4AM エステル(同仁)を含むアッセイ用緩衝液(25mM HEPES(同仁)、Hanks’ balanced salt solution(インビトロジェン)、0.1% 牛血清アルブミン、2.5mM プロベネシド、200μg/mL Amaranth(以上Sigma-Aldrich)、pH7.4)を100μL添加し60分間、37℃、5% CO2にインキュベートした。Fluo-4AM エステルを含むアッセイ用緩衝液を除去したのち、試験化合物は10mMとなるようにジメチルスルホキシドで溶解してアッセイ用緩衝液で希釈後、150μLを添加し、30分間インキュベートした。
リガンドであるヒトオレキシン-Aの2アミノ酸を置換したペプチド(Pyr-Pro-Leu-Pro-Asp-Ala-Cys-Arg-Gln-Lys-Thr-Ala-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2;ペプチド研究所)はhOX1Rに対しては終濃度300pM、hOX2Rに対しては3nMとなるようにアッセイ用緩衝液で希釈し、このリガンド溶液50μLを添加して反応を開始した。反応はFunctional Drug Screening System(FDSS;浜松ホトニクス社製)を用いて各wellの蛍光値を1秒毎に3分間測定し、最大蛍光値を細胞内Ca2+濃度の指標として拮抗活性を求めた。試験化合物の拮抗活性は希釈緩衝液のみを添加したウェルの蛍光値を100%、リガンドおよび化合物を含まない緩衝液を添加したウェルの蛍光値を0%として算出し、種々の濃度の試験化合物を添加した際の蛍光値から、50%阻害濃度(IC50値)を求めた。
本発明化合物のIC50値を表12に示す。
Claims (7)
- 式(IA)
Xは、窒素原子、又は式CHを示し、
Yは下記式群(II)のいずれかを示し、
R2は、水素原子、C1-6アルキル基(ここで、該C1-6アルキル基は、置換基群1から選ばれる1~3個の置換基で置換されてもよい)、C3-6シクロアルキル基、又は4-6員の環状エーテル基を示し、
置換基群1は、ハロゲン原子、C3-6シクロアルキル基、及びC1-6アルコキシ基からなる群であり、
R3は、トリアゾリル基、ピリジル基、又はピリミジニル基を示し、
該トリアゾリル基、ピリジル基及びピリミジニル基は、1~3個のハロゲン原子で置換されてもよく、
R4及びR5は、同一又は異なって水素原子、ハロゲン原子、又はC1-6アルキル基(該C1-6アルキル基は、1~3個のハロゲン原子で置換されてもよい)を示す)
で表されるヘテロ芳香環誘導体、又はその医薬上許容される塩。 - R4が、ハロゲン原子であり、
R5が、水素原子又はハロゲン原子である請求項1に記載のヘテロ芳香環誘導体、又はその医薬上許容される塩。 - 式(I)
Xは、窒素原子、又は式CHを示し、
Yは下記式群(II)のいずれかを示し、
R2は、水素原子、C1-6アルキル基(ここで、該C1-6アルキル基は、置換基群1から選ばれる1~3個の置換基で置換されてもよい)、C3-6シクロアルキル基、又は4-6員の環状エーテル基を示し、
置換基群1は、ハロゲン原子、C3-6シクロアルキル基、及びC1-6アルコキシ基からなる群であり、
R3は、トリアゾリル基、ピリジル基、又はピリミジニル基を示し、
該トリアゾリル基、ピリジル基及びピリミジニル基は、1~3個のハロゲン原子で置換されてもよく、
R4は、水素原子、ハロゲン原子、又はC1-6アルキル基を示す)
で表されるヘテロ芳香環誘導体、又はその医薬上許容される塩。 - Xが、窒素原子であり、
R2が、C1-6アルキル基であり、
R3が、トリアゾリル基、又はピリミジニル基であり、
R4が、ハロゲン原子である請求項1~3のいずれか1項に記載のヘテロ芳香環誘導体、又はその医薬上許容される塩。 - R2が、メチル基、又はエチル基である請求項1~4のいずれか1項に記載のヘテロ芳香環誘導体、又はその医薬上許容される塩。
- 請求項1~5のいずれか1項に記載のヘテロ芳香環誘導体、又はその医薬上許容される塩を有効成分として含有する医薬組成物。
- 請求項1~5のいずれか1項に記載のヘテロ芳香環誘導体、又はその医薬上許容される塩を有効成分として含有する睡眠障害、うつ病、不安障害、パニック障害、統合失調症、薬物依存症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、疼痛、消化器疾患、てんかん、炎症、免疫関連疾患、内分泌関連疾患、又は高血圧の疾患の治療又は予防薬。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12781685.8A EP2708537A4 (en) | 2011-05-10 | 2012-05-08 | HETEROAROMATIC CYCLE DERIVATIVE |
JP2013514014A JPWO2012153729A1 (ja) | 2011-05-10 | 2012-05-08 | ヘテロ芳香環誘導体 |
US14/115,933 US20140081025A1 (en) | 2011-05-10 | 2012-05-08 | Heteroaromatic ring derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011105188 | 2011-05-10 | ||
JP2011-105188 | 2011-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012153729A1 true WO2012153729A1 (ja) | 2012-11-15 |
Family
ID=47139208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/061745 WO2012153729A1 (ja) | 2011-05-10 | 2012-05-08 | ヘテロ芳香環誘導体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20140081025A1 (ja) |
EP (1) | EP2708537A4 (ja) |
JP (1) | JPWO2012153729A1 (ja) |
TW (1) | TW201249830A (ja) |
WO (1) | WO2012153729A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013187467A1 (ja) * | 2012-06-15 | 2013-12-19 | 大正製薬株式会社 | ヘテロ芳香環メチル環状アミン誘導体 |
WO2013187466A1 (ja) * | 2012-06-15 | 2013-12-19 | 大正製薬株式会社 | 分岐鎖アルキルヘテロ芳香環誘導体 |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9499517B2 (en) | 2012-02-07 | 2016-11-22 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
US10828302B2 (en) | 2016-03-10 | 2020-11-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US11059828B2 (en) | 2009-10-23 | 2021-07-13 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016095205A1 (en) | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Heteroaryl orexin receptor antagonists |
US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
EP3336085A1 (en) * | 2016-12-15 | 2018-06-20 | Laboratorios del Dr. Esteve S.A. | Process and intermediate for the preparation of 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007522197A (ja) * | 2004-02-10 | 2007-08-09 | サノフイ−アベンテイス | オレキシン受容体アンタゴニストとしてのピリミジン誘導体 |
WO2010044054A1 (en) * | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
WO2010051237A1 (en) * | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
JP2010520206A (ja) * | 2007-03-02 | 2010-06-10 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピリジンカルボキサミドオレキシン受容体アンタゴニスト |
WO2012008549A1 (ja) * | 2010-07-15 | 2012-01-19 | 武田薬品工業株式会社 | 複素環化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091480A2 (en) * | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
WO2010010186A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
-
2012
- 2012-05-08 EP EP12781685.8A patent/EP2708537A4/en not_active Withdrawn
- 2012-05-08 JP JP2013514014A patent/JPWO2012153729A1/ja active Pending
- 2012-05-08 US US14/115,933 patent/US20140081025A1/en not_active Abandoned
- 2012-05-08 WO PCT/JP2012/061745 patent/WO2012153729A1/ja active Application Filing
- 2012-05-10 TW TW101116659A patent/TW201249830A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007522197A (ja) * | 2004-02-10 | 2007-08-09 | サノフイ−アベンテイス | オレキシン受容体アンタゴニストとしてのピリミジン誘導体 |
JP2010520206A (ja) * | 2007-03-02 | 2010-06-10 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピリジンカルボキサミドオレキシン受容体アンタゴニスト |
WO2010044054A1 (en) * | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
WO2010051237A1 (en) * | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
WO2012008549A1 (ja) * | 2010-07-15 | 2012-01-19 | 武田薬品工業株式会社 | 複素環化合物 |
Non-Patent Citations (2)
Title |
---|
GATFIELD, JOHN: "Orexin Receptor Antagonists: A New Concept In CNS Disorders?", CHEMMEDCHEM, vol. 5, 2010, pages 1197 - 1214, XP009145815 * |
See also references of EP2708537A4 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11059828B2 (en) | 2009-10-23 | 2021-07-13 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators |
US11667644B2 (en) | 2009-10-23 | 2023-06-06 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
USRE48841E1 (en) | 2009-10-23 | 2021-12-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
US9896452B2 (en) | 2012-02-07 | 2018-02-20 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9499517B2 (en) | 2012-02-07 | 2016-11-22 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
RU2639869C2 (ru) * | 2012-06-15 | 2017-12-25 | Тайсо Фармасьютикал Ко., Лтд. | Гетероароматическое метильное производное циклического амина |
WO2013187467A1 (ja) * | 2012-06-15 | 2013-12-19 | 大正製薬株式会社 | ヘテロ芳香環メチル環状アミン誘導体 |
US9266870B2 (en) | 2012-06-15 | 2016-02-23 | Taisho Pharmaceutical Co., Ltd | Heteroaromatic methyl cyclic amine derivative |
WO2013187466A1 (ja) * | 2012-06-15 | 2013-12-19 | 大正製薬株式会社 | 分岐鎖アルキルヘテロ芳香環誘導体 |
US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US11434236B2 (en) | 2016-02-12 | 2022-09-06 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US10828302B2 (en) | 2016-03-10 | 2020-11-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
US11241432B2 (en) | 2016-03-10 | 2022-02-08 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
Also Published As
Publication number | Publication date |
---|---|
EP2708537A1 (en) | 2014-03-19 |
TW201249830A (en) | 2012-12-16 |
US20140081025A1 (en) | 2014-03-20 |
EP2708537A4 (en) | 2014-10-01 |
JPWO2012153729A1 (ja) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012153729A1 (ja) | ヘテロ芳香環誘導体 | |
WO2013187466A1 (ja) | 分岐鎖アルキルヘテロ芳香環誘導体 | |
WO2012081692A1 (ja) | ピラゾール誘導体 | |
US7968571B2 (en) | 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's Disease | |
CA2702647C (en) | Thiopyrimidine-based compounds and uses thereof | |
JP5896319B2 (ja) | ヘテロ芳香環メチル環状アミン誘導体 | |
JP5451633B2 (ja) | トリアゾールオキサジアゾール誘導体 | |
WO2009106980A2 (en) | Indazole derivatives | |
WO2015152367A1 (ja) | オキソ複素環誘導体 | |
WO2013005755A1 (ja) | メチルピペリジン誘導体 | |
JP2008524325A (ja) | 複素環式MCHr1アンタゴニストと療法におけるその使用 | |
JP2014015452A (ja) | ピラゾール誘導体を含有する医薬 | |
JP5930010B2 (ja) | ヘテロ芳香環メチル環状アミン誘導体を含有する医薬 | |
CA2815741A1 (en) | Triazole derivatives as ligands for gaba receptors | |
JP2015131802A (ja) | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 | |
JP2014141480A (ja) | メチルピペリジン誘導体を含有する医薬 | |
JP2014111586A (ja) | ヘテロ芳香環誘導体を含有する医薬 | |
WO2015087993A1 (ja) | オキサゾリジン及びオキサジナン誘導体 | |
WO2017057717A1 (ja) | 複素芳香環誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12781685 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013514014 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14115933 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012781685 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |